APLLTD vs SANOFI: Stock Comparison

Alembic Pharmaceuticals Limited vs Sanofi India Limited

Live data: 22 July 2026, 3:03 PM IST • Source: NSE and company filings

Alembic Pharmaceuticals Limited is the larger company by market capitalisation. Alembic Pharmaceuticals Limited shows faster revenue growth, while Sanofi India Limited shows a lower P/E, a higher ROE and a higher dividend yield. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Side-by-side comparison of Alembic Pharmaceuticals Limited and Sanofi India Limited on live price, valuation, growth, profitability, leverage and quarterly shareholding. Highlighted values mark the more favourable of the two on that metric's usual reading; a single metric is never the full story.

On standard readings, APLLTD is more favourable on 3 of 13 scored metrics and SANOFI on 10These counts are context-free and are not an overall rating.

Key Differences

Market Cap
APLLTD is the larger company
₹16,030 Cr vs ₹7,850 Cr
P/E Ratio
SANOFI has a lower P/E
0x vs 24.3x
P/B Ratio
SANOFI has a lower P/B
0x vs 2.89x
EPS
SANOFI has higher earnings per share
₹134.59 vs ₹34.3
Dividend Yield
SANOFI has a higher dividend yield
7.15% vs 1.42%
Revenue Growth (TTM YoY)
APLLTD has faster revenue growth
4.4% vs -11.9%
EPS Growth (TTM YoY)
APLLTD has faster EPS growth
29.2% vs -14.1%
Qtr Sales Growth
SANOFI has stronger quarterly sales growth
9.74% vs 4.41%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricAPLLTDSANOFI
SectorHealthcareHealthcare
IndustryPharmaceuticalsPharmaceuticals

Price

MetricAPLLTDSANOFI
Live Price₹813.05₹3,415
Day Change-2.47%0.94%
Volume46,79413,127
52-Week High₹1,032.7₹5,955
52-Week Low₹635.8₹3,054
Distance from 52W High-21.27%-42.65%

Valuation

MetricAPLLTDSANOFI
Market Cap₹16,030 Cr₹7,850 Cr
P/E Ratio24.3x0x
P/B Ratio2.89x0x
EPS₹34.3₹134.59
Book Value₹288.7₹325.31
Dividend Yield1.42%7.15%

Growth

MetricAPLLTDSANOFI
Revenue Growth (TTM YoY)4.4%-11.9%
EPS Growth (TTM YoY)29.2%-14.1%
Qtr Sales Growth4.41%9.74%
Qtr Profit Growth40.8%22.4%

Profitability & Leverage

MetricAPLLTDSANOFI
ROE13.4%47.1%
ROCE12.6%49.2%
Net Margin8.98%19.26%
Operating Margin15.2%24.4%
Debt to Equity0.25x0.02x

Shareholding

As of Jun 2026 • change vs previous quarter
MetricAPLLTDSANOFI
Promoter Holding69.36% 0.13 pp0%
FII Holding4.18% 0.07 pp5.64% 0.09 pp
DII Holding15.94% 0.24 pp21.13% 0.18 pp
Public Holding10.01% 0.18 pp12.83% 0.09 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: Alembic Pharmaceuticals Limited and Sanofi India Limited.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.